ORYZON to participate in upcoming events in May and June
Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that it will participate at the following upcoming events:
Bio-Equity Europe 2026, May 4-6
Location: Congress Centre, Prague, Czech Republic
Presentation date and time: May 5, 9:45h CET
Foro Medcap 2026, May 26
Location: Palacio de la Bolsa, Madrid, Spain
Jefferies Healthcare Conference 2026, June 2-4
Location: Marriott Marquis, New York, United States
Presentation date and time: June 4, 8:45h ET
Spring European 'MidCap Event’, June 9
Location: Salons Hoche - Paris, France
Clinical Epigenetics International Conference, June 10-12
Location: Josep Carreras Leukaemia Research Institute, Badalona, Spain
European Hematology Association (EHA) Congress 2026, June 11-14
Location: Stockholmsmässan, Stockholm, Sweden
Presentation date and time: To be later announced
UBS Life Sciences Conference 2026, June 18
Location: London, United Kingdom
BIO International Convention 2026, June 22-25
Location: Convention Center, San Diego, United States
Panel: The Future of Oncology Trials
Panel date and time: June 24, 11:00h – 12:00h PT
ENCALS (European Network to Cure ALS) 2026, June 24-26
Location: IFEMA Palacio Municipal, Madrid, Spain
Presentation date and time: June 25, 16:55h - 18:10h CET (ENCALS Research Forum – Posters Session)